Search Results
Your search for ,WHo matches 20837 pages
Showing 6201 - 6250Selected Poster Presentations From the NCCN 2021 Annual Conference
Although once again, the National Comprehensive Cancer Network® (NCCN®) 2021 Annual Conference could not take place on site in Orlando, researchers presented their work virtually in the form of almost 100 posters. The ASCO Post has summarized some that we found particularly interesting. Many...
Expert Point of View: Thomas Herzog, MD
Discussant of the abstract on this novel algorithm, Thomas Herzog, MD, Deputy Director of the University of Cincinnati Cancer Institute and Professor of Obstetrics and Gynecology at the UC College of Medicine, called the use of risk-based factors in complex ovarian cancer surgery to successfully...
Data Analysis on Early-Onset Colorectal Cancer Sheds Light on the Rising Rates in Young Adults
In May 2021, the U.S. Preventive Services Task Force (USPSTF) announced that it was updating its recommendation for when individuals at average risk of colorectal cancer should begin screening. Echoing the recommendation from the American Cancer Society in 2018, the USPSTF now recommends that those ...
Could Risk-Based Triage System Alter Surgical Practice in Ovarian Cancer?
A simple, risk-assessment algorithm may change practice when it comes to selecting patients with advanced ovarian who can tolerate complex primary debulking surgery, according to data presented during the virtual edition of the Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s...
Lobaplatin- vs Cisplatin-Based Induction and Chemoradiotherapy in Previously Untreated Locoregionally Advanced Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Xing Lv, MD, and colleagues found noninferior progression-free survival with induction therapy with the third-generation platinum lobaplatin/fluorouracil (5-FU) vs cisplatin/5-FU, followed by lobaplatin- vs cisplatin-based...
Global Responses to COVID-19 Pandemic–Related Disruptions in Cancer Care
COVID-19 pandemic–related disruptions in cancer diagnosis, treatment, and research have varied worldwide and so have the responses to those disruptions. During the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care, members of the Global Forum of Cancer...
I Was Given a ‘Death Sentence’ at Just 17
A minor car accident I had with my mother when I was 17 probably saved my life. We were taken to the hospital for a routine checkup, and a subsequent chest x-ray found multiple nodules on my lungs. I underwent dozens of other imaging and blood tests, and finally, my pediatrician suggested my...
Adjuvant Imatinib Therapy Offers Survival Benefit in Patients With Resected GIST, but Team Effort May Be Needed to Reduce Early Discontinuation Rates
Clinical trial data show that adjuvant imatinib improves recurrence-free survival as well as overall survival, when administered for at least 3 years, among patients who undergo a macroscopically complete resection of a primary gastrointestinal stromal tumor (GIST), Chandrajit P. Raut, MD, MSc,...
Medical Oncologist Gouri Shankar Bhattacharyya, MD, FRCP, Dies of COVID-19–Related Complications
The members of the oncology community who spend time and energy addressing the growing global cancer burden in low- and middle-income countries have a kind of selfless dedication beyond the scope of the profession itself. One such medical oncologist was Gouri Shankar Bhattacharyya, MD, FRCP, a...
‘Radiation Is Not the Enemy’
“I want to make very clear that radiation is not the enemy,” Monika Metzger, MD, MSc, emphasized in discussing a study she led on the integration of brentuximab vedotin into the front-line treatment of pediatric patients with high-risk Hodgkin lymphoma. The study yielded excellent results while...
Adding Targeted Agent to Treatment Shows Significant Benefits in Pediatric Patients With High-Risk Hodgkin Lymphoma
Integrating the antibody-drug conjugate brentuximab vedotin into the front-line treatment of pediatric patients with high-risk Hodgkin lymphoma “facilitated significant reduction in radiation exposure and yielded excellent outcomes,” Monika Metzger, MD, MSc, Director for the Central and South...
Disease-Free Survival Benefit With Adjuvant Immunotherapy in Resectable Esophageal Cancer: Practice-Changing for All Patients?
The CheckMate 577 trial—reported in The New England Journal of Medicine by Kelly et al1 and reviewed in this issue of The ASCO Post—is the first global randomized controlled trial for patients with resectable esophageal cancer that showed a significant disease-free survival benefit for adjuvant...
Adjuvant Nivolumab Improves Disease-Free Survival vs Placebo in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemoradiotherapy
As reported in The New England Journal of Medicine by Ronan J. Kelly, MB BCh, MBA, of The Charles A. -Sammons Cancer Center at Baylor University Medical Center, and colleagues, an interim analysis of the phase III CheckMate 577 trial has shown a significant improvement in disease-free survival...
Cabozantinib With Nivolumab for Metastatic Renal Cell Carcinoma: A New Front-Line Standard
The pace of clinical research in metastatic renal cell carcinoma is faster than ever. Over the past 5 years, we have seen data from six phase III clinical trials evaluating combination strategies with checkpoint inhibitors. The era began with data from CheckMate 214, evaluating nivolumab with...
Gustavo Fonseca, MD, FACP, Assumes New Role at Florida Cancer Specialists & Research Institute
Florida Cancer Specialists & Research Institute (FCS) has named Gustavo “Gus” Fonseca, MD, FACP, as Medical Director of the Clinical Research Program. Dr. Fonseca will provide clinical leadership and oversight of the statewide practice’s extensive involvement in conducting phase I through IV...
Atezolizumab Reduces Risk of Disease Progression in Patients With PD-L1–Expressing Early-Stage NSCLC
Atezolizumab given after chemotherapy to patients with resected stage II to IIIA non–small cell lung cancer (NSCLC) significantly improved disease-free survival compared with best supportive care alone in patients whose tumors expressed PD-L1.1 These results of the global phase III IMpower010 trial ...
The Ohio State Recruits Marcos J. de Lima, MD, to Lead Blood and Marrow Transplant and Cellular Therapy Programs
The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central...
Eduardo M. Sotomayor, MD, to Lead New Tampa General Hospital Cancer Institute
Tampa General hospital recently announced the appointment of Eduardo M. Sotomayor, MD, as Director of its newly established Cancer Institute. A pioneer in the field of cancer immunology and immunotherapy and an expert in lymphoma research and treatment, Dr. Sotomayor will lead a team of Tampa...
How the Biden Administration Is Changing Oncology Care
A change in presidential administrations has implications across the health sector, including for oncology. In this column, we review some recent actions by Congress and the Biden administration and their implications for the oncology community. We focus on three areas: funding for patients and...
First Lady Dr. Jill Biden Assures the NCI of the Administration’s Commitment to Advancing Cancer Research
In a virtual visit to the National Cancer Institute (NCI) on February 3, 2021, just 2 weeks after her husband, Joe Biden, was sworn in as the 46th President of the United States, First Lady Jill Biden, EdD, recounted that, in her many years of travel across the United States, she learned that...
Update on Clinical Trials in Acute Myeloid Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on acute myeloid leukemia (AML), such as the use of venetoclax added to...
Nadia Harbeck, MD, PhD, on Early Breast Cancer: Benefit of a De-escalated Regimen
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic complete response and survival in patients with early breast cancer who were treated weekly with a de-escalated 12-week regimen...
APOLLO Trial: Addition of Subcutaneous Daratumumab to Pomalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous daratumumab to pomalidomide/dexamethasone in patients with previously treated multiple myeloma....
Study Finds Need to Improve Knowledge About Palliative Care Among U.S. Adults
The use of palliative care in hospitals in the United States has steadily risen over the past decade, with almost universal access to services in large hospitals and academic medical centers. Despite this increased access and recommendations from ASCO that all patients with advanced cancer receive...
More Widespread Biomarker Testing for NSCLC in Oncology Practices and More Testing in Black Patients: An Urgent Priority
Even though next-generation sequencing is recommended by the National Comprehensive Cancer Network (NCCN) for biomarker testing for patients with non–small cell lung cancer (NSCLC), the uptake among community oncology practices is suboptimal, and the uptake is even lower among Black patients with...
CheckMate 274: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma
As reported in The New England Journal of Medicine by Dean F. Bajorin, MD, and colleagues, an interim analysis of the phase III CheckMate 274 trial has shown improved disease-free survival with adjuvant nivolumab vs placebo among all patients with high-risk muscle-invasive urothelial carcinoma who...
Effect of Time to Surgery on Recurrence and Survival in Clinical Stage I NSCLC
In a retrospective cohort study reported in JAMA Network Open, Heiden et al found that increased time from preoperative diagnostic computed tomography imaging and surgical treatment was associated with an increased risk of disease recurrence and poorer overall survival in patients with clinical...
Lay Health Worker–Led Intervention May Improve Care for Low-Income and Minority Patients With Cancer
In a study reported in JCO Oncology Practice, Manali I. Patel, MD, MPH, and colleagues found that a lay health worker–led intervention was associated with improved documentation of goals of care, increased clinical trial participation, and increased use of palliative care in a population of...
Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma
In a presentation of real-world data given during the 2021 ASCO Annual Meeting, Miron et al concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to...
Does Vitamin D Supplementation Improve Prognosis for Patients With Breast Cancer?
A research team has found that sufficient vitamin D levels at the time of diagnosis may be associated with improved outcomes among people with breast cancer. These findings were presented by Yao et al during the 2021 ASCO Annual Meeting (Abstract 10510). These findings are based on Kaiser...
ADAPT: Survival Outcomes After Neoadjuvant Dual HER2 Therapy for HR-Negative, HER2-Positive Breast Cancer
The first overall survival analysis of the WSG-ADAPT HR-/HER2+ study, which evaluated neoadjuvant therapy in patients with hormone receptor (HR)-negative, HER2-positive breast cancer, showed that treatment with pertuzumab and trastuzumab plus paclitaxel—or the chemotherapy-free regimen of...
Targeting LAG-3 and PD-1 With Relatlimab and Nivolumab: A New Option Under Study in Advanced Melanoma
Immune checkpoint inhibition has been established as an effective treatment for patients with metastatic melanoma. A novel immunotherapeutic combination—this one targeting the LAG-3 (lymphocyte-activation gene 3) and PD-1 immune checkpoints—delayed time to disease progression significantly more...
Use of Integrative Medicine by Patients With Breast Cancer
Nearly three-quarters of patients with breast cancer (73%) reported using at least one type of complementary medicine after cancer diagnosis, while surveyed oncologists believed that less than half (43%) of patients were using these approaches during cancer care. These and other findings from a...
Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Platinum-Based Chemotherapy vs Capecitabine
Ingrid A. Mayer, MD, of Vanderbilt University Medical Center, discusses phase III results from a trial that showed patients with triple-negative breast cancer who had residual invasive disease after neoadjuvant chemotherapy had lower-than-expected invasive disease–free survival, regardless of study ...
Results of a Restrictive Opioid Prescription Protocol for Patients With Cancer Undergoing Surgery
Seeing an opportunity to safely reduce the number of opioid doses prescribed to patients with cancer, researchers proposed a new pain management guideline for all patients undergoing surgery at Roswell Park Comprehensive Cancer Center. The results from the first 6 months of that effort, reported by ...
High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma
Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, were presented by Grossmann et al...
Adjuvant Pembrolizumab Extends Disease-Free Survival in High-Risk Renal Cell Carcinoma
Immunotherapy following surgery significantly improved disease-free survival compared to placebo among patients with high-risk clear cell renal cell carcinoma (RCC), according to results from the international phase III KEYNOTE-564 study presented at the 2021 ASCO Annual Meeting by Toni K....
Efficacy of Platinum Chemotherapy vs Capecitabine for Basal-Like Triple-Negative Breast Cancer
About 80% of triple-negative breast cancers are classified as the subtype basal-like. Typically, patients with triple-negative breast cancer receive chemotherapy before surgery. The presence of residual cancer in the breast after chemotherapy signals a higher likelihood that the cancer will...
Remote Monitoring Program Reduced Hospitalization Among Patients With Cancer Infected With COVID-19
A study by researchers at Mayo Clinic Cancer Center found that patients with cancer diagnosed with COVID-19 who received care at home via remote patient monitoring were significantly less likely to require hospitalization for their illness, compared to patients with cancer infected with the virus...
Extended Follow-up of Nivolumab/Ipilimumab for Metastatic Melanoma
In the longest follow-up results from a clinical trial of combination immunotherapy for metastatic melanoma, investigators report that nearly half the patients who received the drugs nivolumab and ipilimumab were alive at a median of 6.5 years after treatment. These long-term results from the...
OUTBACK Trial: No Survival Benefit With Adjuvant Chemotherapy After Standard Chemoradiation for Locally Advanced Cervical Cancer
Cervical cancer is the fourth most common cancer in women worldwide, and the leading cause of cancer-related death among women in Eastern, Western, Middle, and Southern Africa. Globally, in 2018, approximately 570,000 women were diagnosed with cervical cancer, and 311,000 women died. In the United...
Sotorasib for KRAS G12C–Mutated NSCLC: Overall Survival and Exploratory Subgroup Analyses
Results from the phase II cohort of the CodeBreaK 100 study showed that treatment with the KRAS G12C inhibitor sotorasib achieved a 37.1% objective response rate and a median overall survival of 12.5 months in previously treated patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC)....
Study Examines Relationship Between Risk of COVID-19 Infection and Breast Cancer Treatment
In a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center involving more than 3,000 women treated for breast cancer at the height of the COVID-19 pandemic in New York City, only 64 patients, or 2% of the total study population, contracted the virus. Of this group, 10 died ...
Transoral Surgery Followed by Lower-Dose Radiation in Patients With HPV-Associated Oropharyngeal Cancer at Intermediate Risk of Recurrence
The phase II E3311 trial offers new information about using reduced-intensity treatment in patients with human papillomavirus (HPV)-associated oropharyngeal cancer who are at intermediate risk of recurrence. These findings were presented by Robert L. Ferris, MD, PhD, and colleagues during the 2021...
Toni K. Choueiri, MD, on Renal Cell Carcinoma: Pembrolizumab vs Placebo in Adjuvant Treatment
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses phase III results from KEYNOTE-564, which evaluated the safety and efficacy of pembrolizumab in the adjuvant treatment of patients with renal cell carcinoma who have undergone nephrectomy for intermediate-high or high-risk disease or...
OlympiA: Adjuvant Olaparib Extends Disease-Free Survival in BRCA-Mutated Early-Stage HER2-Negative Breast Cancer
One year of adjuvant therapy with the PARP inhibitor olaparib extended disease-free survival in patients with high-risk, early-stage, HER2-negative breast cancer with BRCA1/2 germline mutations, according to a prespecified interim analysis of the phase III OlympiA trial presented by Andrew Tutt, MB ...
Ponatinib/Blinatumomab Demonstrates High Rates of Complete Molecular Response in Philadelphia Chromosome–Positive ALL
The combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL). The study—presented by Nicholas J. Short, MD, and colleagues during the 2021 ASCO...
Community-Based Engagement Initiative Improves Accrual of Black Participants in Clinical Trials
A 5-year community outreach and engagement effort by the Abramson Cancer Center at the University of Pennsylvania to increase enrollment of Black patients into cancer clinical trials more than doubled the percentage of participants, improving access and treatment for a group of patients with...
The Daughter of a Fighter Pilot Becomes a Leader in Compassionate Cancer Care
Jamie H. Von Roenn, MD, FASCO, grew up in the suburbs of Chicago as the middle child of three girls. She was, by her own account, extremely shy by nature. Her mother was a graduate of the University of Chicago, but her father’s college education was preempted by his service as a fighter pilot in...
Working on the Night Shift, a Connection to a Patient With Cancer Inspires a Career
Jaap Verweij, MD, PhD, FASCO, was born in 1953 in Velsen, a municipality situated on both sides of the massive North Sea Canal in the Netherlands. His father was a sea captain, and other close family members also plied the oceans for a living in the fishing or transport industries. Dr. Verweij...
